Market Regional Insights
North America is expected to holddominant position in BioreactorsMarket due to presence of major biopharmaceutical manufacturing companies.Biopharmaceutical companies such as Gilead Science, Inc., Amgen, and Biogen,Inc. in the U.S. actively conducts research on novel therapies for thetreatment of various diseases. Research of therapies associated with oncologysuch as monoclonal antibodies require usage of bioreactors on small as well aslarge scale for production purposes. Furthermore, according to the NationalCentre for Biotechnology Information (NCBI), in 2014, 65.6% of the clinicalscale manufacturers and around 42% of the commercial manufacturers usedsingle-use bioreactors to improve their bioprocessing. Europe is expected towitness significant growth rate in the bioreactors market due to increasingusage of bioreactors in biopharmaceutical companies. According to theOrganization for Economic Co-operation and Development (OECD), in 2015, around1,700 biopharmaceutical companies, which utilize bioreactors, are from Europe.
Bioreactor is an engineered ormanufactured vessel that is used in the production of wide range of biologicalproducts. Industrial bioreactor is a vessel in which biochemical process iscarried out using microbes and animal cells or biologically active compoundsthat are derived from living cells. Bioreactors are cylindrical in shape withcapacity of liters to cubic meters and is the most important component involvedin bioprocessing. Fermentation processes such as wine, and beer production arecarried out in bioreactors. Bioreactors for large scale production of therapeuticproducts are made of stainless steel. In biopharmaceutical companies, smallglass bioreactors are used for research and development purpose and for scaleup activities. Another type of bioreactors are disposable bioreactors, whichare meant for single use and hence are called as single-use bioreactors. It isgenerally used for extensive research and manufacturing. Bioreactors canoperate in batch, fed batch, and continuous stirred tank processes. Bioreactorsare used to produce therapeutics, which include monoclonal antibodies,vaccines, stem cells, and gene modified cells.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1593
Market Drivers
The efficiency of single-usebioreactors has increased across pharmaceutical industries in terms ofproduction, quality control, and procurement. Single-use bioreactors offeradvantages such as consistency in production, increase in speed of manufacturing,reduced operational cost, and reduction in manufacturing time of finisheddosage form, which foster growth of bioreactors market. In 2016, as per theNational Centre for Biotechnology Information (NCBI), operational cost per gramof monoclonal antibody production (mAb) for single-use bioreactor is around 22%lower than conventional system, mainly due to less labor, utilities,maintenance, and waste. For commercial scale of monoclonal antibody production(mAb), conventional fed-batch bioreactors usually require 10000L – 25000Lstainless steel tank to culture cells and produce yield of 2-6 g/L. However,single-use bioreactors employ continuous cell culture supply in 500L - 2000Ltank and produces 10 - 30 times higher cell density. Therefore, more quantity ofproducts can be produced by using this single-use bioreactors, with less spaceand capital cost. Other factors thatcontribute to growth of the market include low water usage by single-usesystems, less floor space requirement, and low risk of cross contamination insingle-use system. Furthermore, in 2016, a case study by Cambridge HealthtechInstitute stated that by using single-use (SU) bioreactors, there can be anannual savings of US$ 250,000 in water generation for injections and US$ 60,000in labor time required to set up and cleaning of stainless steel tank. Thesefactors are expected to drive growth of the bioreactors market over theforecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/bioreactors-market-1593
Moreover, in bioprocessing,enzymes used are specific in their action and produce a pure product. Diseasessuch as diabetes and anemia are widespread globally, and according to the WorldHealth Organization (WHO), in 2014, around 415 million people were living withdiabetes, which indicates the need for increasing availability of bioprocessedproducts at faster rates, wherein, advanced bioreactors could be useful. Forinstance, bioprocessed products such as Amaryl manufactured by Sanofi AventisU.S. Llc, and Acarbose by Emcure Pharmaceutical Ltd. are used as anti-diabeticdrugs. Thus, implementation of single-use bioreactors has made clinical andcommercial production of biopharmaceuticals fast and efficient in limited timeand has reduced the cost associated with production, in turn driving growth ofbioreactors market.
Key players operating inbioreactors market include Thermo Fisher Scientific, Inc., Merck KGaA, GEHealthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris,Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and AppplikonBiotechnology, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1593
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
